How many stocks are there of Immuron?
The current number of stocks of Immuron is 227.8 M undefined.
Immuron Stocks 2024
Immuron Stocks
227.8 M
Ticker
IMC.AX
ISIN
AU000000IMC7
WKN
A0RDPK
In 2024, Immuron had 227.8 M outstanding stocks, a 0.1% change from the 227.58 M stocks in the previous year.
The Immuron Stocks history
| YEAR | NUMBER OF STOCKS (undefined AUD) |
|---|---|
| 2023 | 227.8 |
| 2022 | 227.58 |
| 2021 | 221.06 |
| 2020 | 176.39 |
| 2019 | 144.74 |
| 2018 | 133.66 |
| 2017 | 105.87 |
| 2016 | 76.44 |
| 2015 | 75.58 |
| 2014 | 42.22 |
| 2013 | 14.33 |
| 2012 | 13.92 |
| 2011 | 12.75 |
| 2010 | 10.62 |
| 2009 | 5.51 |
| 2008 | 4.26 |
| 2007 | 3.97 |
| 2006 | 3.75 |
| 2005 | 3.7 |
| 2004 | 3.28 |
Immuron shares outstanding AU000000IMC7 · A0RDPK
The number of shares was Immuron in 2023 — This indicates how many shares 227.798 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Immuron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Immuron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Immuron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immuron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 3.28 M Aktien |
| 2005 | 3.7 M Aktien |
| 2006 | 3.75 M Aktien |
| 2007 | 3.97 M Aktien |
| 2008 | 4.26 M Aktien |
| 2009 | 5.51 M Aktien |
| 2010 | 10.62 M Aktien |
| 2011 | 12.75 M Aktien |
| 2012 | 13.92 M Aktien |
| 2013 | 14.33 M Aktien |
| 2014 | 42.22 M Aktien |
| 2015 | 75.58 M Aktien |
| 2016 | 76.44 M Aktien |
| 2017 | 105.87 M Aktien |
| 2018 | 133.66 M Aktien |
| 2019 | 144.74 M Aktien |
| 2020 | 176.39 M Aktien |
| 2021 | 221.06 M Aktien |
| 2022 | 227.58 M Aktien |
| 2023 | 227.8 M Aktien |
Immuron Aktienanalyse
What does Immuron do?
Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Immuron's Shares Outstanding
Immuron's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Immuron’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Immuron’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Immuron’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Immuron stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Immuron are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Immuron evolved in recent years?
The number of shares of Immuron has increased by 0.1% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Immuron as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Immuron?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Immuron pay?
Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immuron?
The current dividend yield of Immuron is .
When does Immuron pay dividends?
Immuron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immuron?
Immuron paid dividends every year for the past 0 years.
What is the dividend of Immuron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immuron located?
Immuron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immuron from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Immuron pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Immuron in the year 2023?
In the year 2023, Immuron distributed 0 AUD as dividends.
In which currency does Immuron pay out the dividend?
The dividends of Immuron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immuron
Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
